BRAF and colorectal carcinoma: The first large trials were presented by Grothey et al. Overall, 445 BRAF wild-type CRC patients included in the MODUL trial were randomly assigned to receive maintenance therapy with fluoropyrimidine and bevacizumab with or without atezolizumab after induction first-line treatment with FOLFOX plus bevacizumab.